Preclinical News and Research

RSS

Treating diabetics with pig islet cells

As the fourth-leading cause of death in developed countries, diabetes can truly be called a modern-day plague.

9 Jan 2008

NicOx extends ophthalmology agreement with Pfizer

NicOx S.A. has announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research in the field of ophthalmology.

9 Jan 2008

Taranabant shows promise for weight loss in obese people

The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses.

9 Jan 2008

Magen BioSciences licenses dermatology compounds from Lilly

Magen BioSciences, Inc., a privately held specialty pharmaceutical company focused on developing pharmaceuticals to treat diseases of the skin, announced today that it had acquired the rights to a series of novel pre-clinical compounds from Eli Lilly and Company.

8 Jan 2008

Baxter to develop recombinant Factor IX proteins to treat hemophilia B

Baxter International Inc. has announced that it has initiated pre-clinical programs to develop recombinant Factor IX proteins to treat hemophilia B.

From Baxter International Inc. 7 Jan 2008

Genmab announces HuMax-CD32b pre-clinical program

Genmab A/S has announced a new pre-clinical antibody program called HuMax-CD32b. This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors.

7 Jan 2008

Sanofi Pasteur enters agreement eith Crucell for next-generation biologicals against rabies

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

4 Jan 2008

Cardiac stem cell therapy research

Since the year 2000, much has been learned about the potential for using transplanted cells in therapeutic efforts to treat varieties of cardiac disorders.

28 Dec 2007

Researchers advance stem cell gene therapy

Ireland Cancer Center of University Hospitals Case Medical Center researchers have recently made great strides in stem cell gene therapy research by transferring a new gene to cancer patients, via their own stem cells, with the ultimate goal of being able to use stronger chemotherapy treatment with less severe side effects.

13 Dec 2007

Cell-tracking software speeds drug development

Time is money, especially in the race to discover new anti-inflammatory drugs and bring them to market.

13 Dec 2007

Resverlogix receives FDA approval to start clinical trial for RVX-208

Resverlogix Corp. has announced that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL.

10 Dec 2007

FDA approves trial for SKCC breast cancer vaccine

The Federal Drug Administration announced Friday approval of a Phase 1 clinical trial designed to study a breast cancer vaccine developed at the Sidney Kimmel Cancer Center.

10 Dec 2007

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

UCB has announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta, administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo.

4 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

Purified bacterial extract sprayed into lungs ramps up innate immune system

A purified extract prepared from a common microbe and delivered to the lungs of laboratory mice in a spray set off a healthy immune response and provided powerful protection against all four major classes of pathogens including those responsible for anthrax and bubonic plague, according to a presentation at the American Society for Cell Biology's 47th Annual Meeting.

4 Dec 2007

Inhaled immune system stimulant launches immune response in lungs to wipe out lethal infections

An inhaled immune system stimulant protects mice against lethal pneumococcal pneumonia and other deadly bacterial, viral and fungal infections of the lungs, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at a major scientific meeting.

4 Dec 2007

Vaccinex receives new European patent for antibody discovery technology

Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.

3 Dec 2007

FDA approves Cymbalta for maintenance treatment of major depressive disorder

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

2 Dec 2007

AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX (anastrozole)

AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010.

2 Dec 2007

Sirtris Pharmaceuticals unveils promising, novel SIRT1 activators for treating diseases of aging

Sirtris Pharmaceuticals has announced that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.

29 Nov 2007